Pregled bibliografske jedinice broj: 312029
Analysis of Pgp/MDR1 activity and molecular response in chronic myelogenous leukemia (CML) cells treated with Imatinib mesylate
Analysis of Pgp/MDR1 activity and molecular response in chronic myelogenous leukemia (CML) cells treated with Imatinib mesylate // Book of abstracts of the 2007 Annual Meeting of the Croatian Immunological Society
Zagreb, 2007. str. 35-35 (poster, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 312029 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Analysis of Pgp/MDR1 activity and molecular response in chronic myelogenous leukemia (CML) cells treated with Imatinib mesylate
Autori
Svoboda-Beusan, Ivna ; Ajduković, Radmila ; Kušec, Rajko ; Sabioncello, Ante ; Bendelja, Krešo
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Book of abstracts of the 2007 Annual Meeting of the Croatian Immunological Society
/ - Zagreb, 2007, 35-35
Skup
2007 Annual Meeting of the Croatian Immunological Society
Mjesto i datum
Rovinj, Hrvatska, 19.10.2007. - 21.10.2007
Vrsta sudjelovanja
Poster
Vrsta recenzije
Domaća recenzija
Ključne riječi
multidrug resistence; Pgp; MDR; CLL
Sažetak
Imatinib mesylate (IM) is a specific inhibitor of the BCR-ABL tirosine kinase. The treatment goal of IM in CML is clinical, hematological and molecular remission of the disease. However, we have previously shown that IM treatment could induce multidrug resistance (MDR) where the membrane transporter P glycoprotein (Pgp) decreases treatment success through amplified efflux of IM. In order to elucidate the mechanism of MDR induction by evaluating it through a longer period, we observed observed the effect of IM monotherapy (400-600mg/day), and the variations in the activity of Pgp pump and then compared them with molecular response kinetics. Pgp activity of bone marrow and peripheral blood cells MDR was observed in 14 CML patients with flow cytometric rhodamine dye efflux test and the result was expressed as the ratio of minimal and real pump activity (RMF, rang of values 0, 6-1, 3) where RMF>1 expressed the elevated activity. The kinetics of molecular response was measured by quantitative RT-PCR method (TaqMan) and the results were divided in 4 rangs: R1 complete molecular remission (PCR neg) in 5 (35%) patients, R2 (major response in one (7%), R3 (minor response in 3 (22%) and with weak response or without any response at all in 5 (35%) patients in R4 range. All R1 patients had low Pgp activity whereas the greatest activity increase was observed in R4. The correlation between MDR and RT-PCR was determined and confirmed with rang correlation (rs=0, 66 ; p<0, 001). We conclude that rhodamine test of Pgp activity has clinical value and correlates with the disease activity measured by molecular level of oncogene BCR-ABL chimeric genes.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
021-0212432-2436 - Rezistencija na lijekove (Svoboda-Beusan, Ivna, MZOS ) ( CroRIS)
Ustanove:
Imunološki zavod d.d.,
Klinička bolnica "Dubrava"
Profili:
Ante Sabioncello
(autor)
Krešo Bendelja
(autor)
Ivna Svoboda-Beusan
(autor)
Rajko Kušec
(autor)